Accuracy of CardioWatch 287-2 During Profound Hypoxia (ACW2)

In an individual's SpO2 range from 100 to 73 %, this study calibrates and evaluates the accuracy of SpO2 measurement by CW2 in comparison to reference pulse oximeter (Nellcor PM10) or CO-oximetry, Pulse rate (PR) and respiratory rate (RR) were calibrated based on the same Nellcor equipment and the frequency of end-tidal CO2 respectively.

Study Overview

• Status: Completed
• Conditions: Hypoxia
• Intervention / Treatment: Device: CardioWatch 287-2

Detailed Description

The study is designed in accordance with Medical electrical equipment - Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment ISO 80601-2-61:2017, Corrected version 2018-02 and ISO 80601-2-55.

SpO2: Testing to confirm the accuracy of the SpO2 monitoring according to ISO 80601-2-61 Clause 201.12.1.101 201.12.1.101

RR Testing: Testing to confirm the accuracy of the respiration rate monitoring according to ISO 80601-2-55. Volunteers respirated spontaneously, no efforts were made to include all ranges of respiration during the study.

PR Testing: Testing to confirm the accuracy of the PR monitoring according to ISO 80601-2-61 Clause 201.12.1.104. No efforts were made to influence PRs of volunteers.

An accelerometer and PPG filters are built in CW2 in order to form the basis to exclude non-eligible test results.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Genk, Belgium, 3600
    • Complementair Medisch Centrum (CMC) Europe

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy non-disabled subjects with American Society of Anesthesiologists health score (ASA) of 1 or 2.
2. The subject is aged ≥18 and ≤ 65 years.
3. The subject is not intellectual disabled, and has provided informed consent and is willing to comply with the study procedures.

Exclusion Criteria:

1. Heavy smokers or individuals exposed to high levels of carbon monoxide that result in elevated carboxyhemoglobin levels.
2. Individuals subject to conditions that result in elevated levels of methemoglobin
3. Individuals with hypoxia (SpO2 < 95 % at 21 % of oxygen)
4. Severe claustrophobia
5. Subject is known with altitude disease
6. The subject is obese (BMI ≥ 31 kg/m2).
7. The subject has a known history of moderate to severe heart disease, lung disease, kidney or liver disease.
8. The subject is diagnosed with moderate to severe asthma.
9. The subject is known with a hemoglobinopathy or history of anemia, e.g. sickle cell anemia, thalassemia, ... who, in the opinion of the investigator, would make them unsuitable for study participation.
10. The subject has any other serious systemic illness.
11. Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators would interfere with the sensors working correctly.
12. The subject has a history of fainting or vasovagal response.
13. The subject has a history of sensitivity or allergy to local anesthetics or disinfectants.
14. The subject has a diagnosis of Raynaud's disease.
15. The subject has unacceptable collateral circulation based on exam by the investigator.
16. The subject is pregnant, lactating or trying to get pregnant.
17. The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with study procedures.
18. The subject has any other condition, which in the opinion of the investigators would make the subject unsuitable for the study.
19. The subject refuses to remove nail-vanish.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Single group; Each participant wore one CW2 sensor attached to the back of the wrist with a wrist band. Additionally, each participant wore a reference pulse oximeter (Nellcor PM10) attached to the middle finger of the ipsilateral hand. This enabled the comparison of the paired results of the CW2 sensor and reference pulse oximeter equipment for SpO2 measurements at different oxygen saturation levels. Twelve subjects of the 24 participants received an arterial catheter in the contralateral radial artery for exvivo SaO2 determination by CO-oximetry and in order to define the final accuracy of CW2 for SpO2 measurement.

Device: CardioWatch 287-2; CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulse Oximetry	SpO2	1 hour
Pulse rate	Heart rate in beats per minutes	1 hour
Respiratory rate	In breaths per minutes	1 hour

Collaborators and Investigators

• Sponsor: Corsano Health B.V.
• Collaborators: Ziekenhuis Oost-Limburg
• Investigators: Principal Investigator: Raf de Jongh, MD, PhD, Ziekenhuis Oost-Limburg

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2022
• Primary Completion (Actual): June 18, 2022
• Study Completion (Actual): June 27, 2022

Study Registration Dates

• First Submitted: September 9, 2022
• First Submitted That Met QC Criteria: September 13, 2022
• First Posted (Actual): September 15, 2022

Study Record Updates

• Last Update Posted (Actual): September 15, 2022
• Last Update Submitted That Met QC Criteria: September 13, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: accuracy; heart rate; respiratory rate; oxygen saturation; SpO2; PPG; wrist wearable; Corsano; CardioWatch 287-2
• Additional Relevant MeSH Terms: Signs and Symptoms, Respiratory; Hypoxia
• Other Study ID Numbers: CIV-21-12-038447

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No